You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

23 Results
Guidelines and Advice
Status: Current
ID: MCC
Jun 2006
Guidelines and Advice
Aug 2006
Guidelines and Advice
May 2006
Guidelines and Advice
Guidelines and Advice
Guidelines and Advice
Guidelines and Advice
Apr 2006
Guidelines and Advice
Status: Current
ID: GL-C50-03
Apr 2006
Statistical Reports
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Palliative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - Relapsed or Refractory Hodgkin Lymphoma
New
Jan 2026
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Updated
Jan 2026

Pages